Determination of the cytotoxic effect of Clostridium histolyticum culture supernatant on HeLa cells in the presence of protease inhibitors

FEMS Immunology and Medical Microbiology

Volumn 45, Issue 2, 2005, Pages 137-142

  Jóźwiak, Jarosław ^a   Komar, Aldona ^a   Jankowska, Ewa ^a   Martirosian, Gayane ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Clostridium histolyticum; Protease inhibitor; Supernatant cytotoxicity

Indexed keywords

APROTININ; BENZYLSULFONYL FLUORIDE; CHYMOSTATIN; CLOSTRIPAIN; POTASSIUM; PROTEINASE INHIBITOR; TOSYLLYSYL CHLOROMETHYL KETONE; TOXIN;

ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CLOSTRIDIUM HISTOLYTICUM; CONTROLLED STUDY; CYTOTOXICITY; DEFENSE MECHANISM; ENZYME ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

APROTININ; BACTERIAL TOXINS; CELL DEATH; CLOSTRIDIUM HISTOLYTICUM; CULTURE MEDIA, CONDITIONED; CYSTEINE ENDOPEPTIDASES; HELA CELLS; HUMANS; OLIGOPEPTIDES; PROTEASE INHIBITORS; TOSYL COMPOUNDS; TOSYLLYSINE CHLOROMETHYL KETONE;

EID: 22844433192     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2005.03.005     Document Type: Article

References (20)

1. B. Durmaz, H.E. Ahel, E. Sonmez, R. Turkoz, and E. Aydin Infective endocarditis due to Clostridium histolyticum Clin. Microbiol. Infec. 6 2000 561 563
2. J.A. Jones, J.E. Salmon, and D. Djuretic An outbreak of serious illness and death among injecting drug users in England during 2000 J. Med. Microbiol. 51 2002 978 984
3. J.S. Brazier, M. Gai, and T.E. Morris Outbreak of Clostridium histolyticum infections in injecting drug users in England and Scotland Euro. Surveill. 1 2004 1 9
4. E. Yoshida, and H. Noda Isolation and characterization of collagenases I and II from Clostridium histolyticum Biochim. Biophys. Acta 105 1965 562 574
5. L.G. Sparrow, and A.B. McQuade Isolation by affinity chromatography of neutral protease from Clostridium histolyticum Biochim. Biophys. Acta 302 1973 90 94
6. M.R. Kula, D. Hatef-Haghi, M. Tauber-Finkelstein, and S. Shaltiel Consecutive use of ω-aminoalkylagaroses. Resolution and purification of clostripain and collagenase from Clostridium histolyticum Biochem. Biophys. Res. Commun. 69 1976 389 396
7. E. Kessler, and A. Yaron A novel aminopeptidase from Clostridum histolyticum Biochem. Biophys. Res. Commun. 50 1973 405 412
8. I. Mandl, J.D. Maclennan, and E.L. Howes Isolation and characterization of proteinase and collagenase from Clostridium histolyticum J. Clin. Invest. 32 1953 1323 1329
9. S. Moskalewski, K.R. Sochanska, and T. Wiwatowski The presence of a factor toxic to pancreatic β cells in some collagenase preparations Bull. Acad. Pol. Sci. Biol. 22 1974 127 130
10. J.G. Pasternack, and Q.A. Bengston The experimental pathological changes produced by the toxin of Clostridium histolyticum in animals Pub. Health Rep. 55 1940 775
11. H.E. Bowen A comparison of the lethal and hemolytic toxins of Clostridium histolyticum Yale J. Biol. Med. 25 1952 131 138
12. T. Hefley, J. Cushing, and J.S. Brand Enzymatic isolation of cells from bone: cytotoxic enzymes of bacterial collagenase Am. J. Physiol. 240 1981 C234 C238
13. D.A. Flick, and G.E. Gifford Comparison of in vitro cell cytotoxic assays for tumor necrosis factor J. Immunol. Meth. 68 1984 167 175
14. W. Porter, L. Cunningham, and W. Mitchell Studies on the active site of clostripain. The specific inactivation by the chloromethyl ketone derived from a-N-tosyl-l-lysine J. Biol. Chem. 246 1971 7675 7682
15. E.L. Howes, I. Mandl, and S. Zaffuto Toxicity of enzymes from Clostridium histolyticum J. Bacteriol. 79 1960 191 197
16. H. Umezawa, T. Aoyagi, H. Morishima, S. Kunimoto, and M. Matsuzaki Chymostatin, a new chymotrypsin inhibitor produced by actinomycetes J. Antibiot. (Tokyo) 23 1970 425 427
17. K.B. Park, and R.G. Labbe Proteolysis of Clostridium perfringens type A enterotoxin during purification Infect. Immun. 58 1990 1999 2001
18. S. Kobayashi, S. Kondo, and K. Juni Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers Pharm. Res. 11 1994 1239 1243
19. C. Westberg, K. Benkestock, A. Fatouros, M. Svensson, and B. Sjostrom Hexarelin - evaluation of factors influencing oral bioavailability and ways to improve absorption J. Pharm. Pharmacol. 53 2001 1257 1264
20. J. Xu, T. Lister, W.M. Purcell, and D.E. Ray Neurotoxic potentiation is related to a metabolic interaction between p-bromophenylacetylurea and phenylmethanesulfonyl fluoride Toxicol. Appl. Pharmacol. 157 1999 222 226